Observing the progression of cystic fibrosis lung disease in young patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to characterize the early lung disease associated with cystic fibrosis (CF) in newborns, infants, and toddlers. It will include patients diagnosed through newborn screening or other means within the first four months of life, and compare their data with those diagnosed later. The study will collect data from routine check-ups, including imaging, pulmonary function tests, and microbiological assessments, to understand the onset and natural progression of CF lung disease. The goal is to identify factors influencing the disease course and the impact of early diagnosis and treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Newly diagnosed patients with Cystic Fibrosis (CF). Diagnosis of CF: at least one of the following three international accepted criteria is fulfilled: i) sweat chloride ≥ 60mEq/L and/or ii) 2 CF-causing mutations in the CFTR gene and/or iii) changes typical for CF in the transepithelial potential difference in nasal or rectal epithelium.
2. Age and mode of diagnosis:

   * Early diagnosed (ED): Initial diagnosis following CF-NBS or for other reasons in the first 4 months of life (in preterms corrected age of 4 months) after January 1st, 2006. Other reasons could be prenatal diagnostics, meconium ileus or positive family history.
   * Late diagnosed (LD): Diagnosed after the fourth month of life due to clinical symptoms; initial diagnosis after January 1st, 2006.

Exclusion Criteria:

All patients are excluded who themselves or whose parents do not want to participate or that withdraw from the study; or those in whom the diagnosis of CF is unsure.

Further exclusion criteria are:

1. Preterms \<30th week of gestation
2. Longer period of mechanical ventilation in first 3 months of life
3. A significant medical disease or condition other than CF likely to interfere with the child's ability to complete the entire protocol
4. Previous major surgery except for meconium ileus or atresia of the intestine
5. Other major organ dysfunction, excluding pancreatic or hepatic dysfunction or another condition due to CF
6. Physical findings that would compromise the safety of the subject or the quality of the study data as determined by investigator
7. Chronic lung disease other than CF (e.g. bronchopulmonary dysplasia)
8. History of adverse reaction to medication for sedation or known claustrophobia

Criteria, which lead to a displacement of the procedures in sedation until the child has recovered: - Clinically significant upper airway obstruction as determined by investigator (e.g.

severe laryngomalacia, markedly enlarged tonsils, significant snoring, diagnosed obstructive sleep apnoea)

\- Severe gastroesophageal reflux, defined as persistent frequent emesis despite anti-reflux therapy

Where it's running

• University Children's Hospital Heidelberg, Cystic Fibrosis Centre
  Heidelberg, Baden-Wurttemberg, Germany Recruiting
• University Hospital Gießen and Marburg GmbH
  Giessen, Hesse, Germany Recruiting
• Medizinische Hochschule Hannover
  Hanover, Lower Saxony, Germany Recruiting
• University Children's Hospital Schleswig-Holstein
  Lübeck, Schleswig-Holstein, Germany Recruiting

Study contacts

• Principal investigator: Marcus A Mall, MD — University Hospital Heidelberg
• Study coordinator: Marcus A Mall, MD
• Email: Marcus.Mall@med.uni-heidelberg.de
• Phone: +49 6221 56 4502

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Identifying new biological markers for lung disease in cystic fibrosis patients

  This study is trying to find new biological markers in cystic fibrosis patients to better understand and track lung disease caused by Mycobacterium abscessus.

  Recruiting Ospedale San Raffaele · Milan, MI · NCT06413459

• Investigational gene therapy for adults with cystic fibrosis

  This study is testing a new gene therapy for adults with cystic fibrosis who have severe lung disease and can't use current treatments, to see if it helps improve their health.

  Recruiting at 18 sites Phase 2 4D Molecular Therapeutics · Birmingham, Alabama and 19 other locations · NCT05248230

• Using breath analysis to identify multiple lung diseases

  This study is testing if analyzing breath samples can help identify different lung diseases like lung cancer and COPD in a large group of 10,000 people.

  Recruiting ChromX Health · Guangzhou, Guangdong · NCT06528418

• Using ultrasound-based measures to check liver health in children

  This project will test whether ultrasound techniques like shear wave elastography, shear wave dispersion, and attenuation imaging can noninvasively characterize liver disease in children who have or may have liver problems.

  Recruiting Sahlgrenska University Hospital · Gothenburg, Västra Götaland County · NCT07202910

• Gut response to a Mediterranean diet in children with cystic fibrosis

  This project will try a Mediterranean-style diet in children with cystic fibrosis to see if it lowers gut inflammation, shifts the gut microbiome toward healthier bacteria, and supports better nutrition.

  Recruiting Dartmouth-Hitchcock Medical Center · Lebanon, New Hampshire and 1 other locations · NCT07223255

• Registry for Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease

  This study is collecting information from people with idiopathic pulmonary fibrosis and other lung diseases to better understand their experiences and health over several years.

  Recruiting at 39 sites Duke University · Birmingham, Alabama and 46 other locations · NCT01915511

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.